Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients.
about
Efavirenz and the CNS: what we already know and questions that need to be answeredNeurological and psychiatric adverse effects of antiretroviral drugs.Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.Neuropsychiatric Effects of HIV Antiviral Medications.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionThe Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 InfectionAntiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.An update on the use of Atripla in the treatment of HIV in the United States.Clinical utility of current NNRTIs and perspectives of new agents in this class under development.HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014.Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.Evaluation of a sex-based difference in the pharmacokinetics of digoxin.Efavirenz: a decade of clinical experience in the treatment of HIV.Annular erythema and photosensitivity as manifestations of efavirenz-induced cutaneous reactions: a review of five consecutive cases.Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.Implications of efavirenz for neuropsychiatry: a review.A systematic review of the psychiatric side-effects of efavirenz.Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.Impact of pharmacogenetics on CNS side effects related to efavirenz.Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia.Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.Real-life rilpivirine resistance and potential emergence of an E138A-positive HIV strain in north-eastern France.The disposition and metabolism of GW695634: a non-nucleoside reverse transcriptase inhibitor (NNRTi) for treatment of HIV/AIDS.Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.Recreational substance use and tolerance of efavirenz in HIV-1 infected patients.Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study.Incidence and risk factors for neuropsychiatric events among Ghanaian HIV patients on long-term non-nucleoside reverse transcriptase inhibitor-based therapy.Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz.HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study
P2860
Q28085028-387B38EC-090E-4C4D-8ADD-DF8A6DD936C5Q34039419-EB939CB5-FA0C-4C4C-BBC1-AF7D6FA107CEQ34464997-0E9EC800-BF27-4B4C-B709-6CF16906E3ECQ34537705-3BF99617-3996-4CCF-A12B-48D5E28F032BQ34756398-3962BA4E-E39E-447C-98F0-7FB2FCCC3602Q34976284-1B9A534E-04D4-422B-9BE6-1C32B7652350Q35111300-D7EDC34E-1026-4A39-A53F-01D9D479F05DQ35547048-C8E649B6-DD83-47DE-8F7F-B44C575FC9BEQ35557269-5512B063-6697-4E2F-970F-89F65C25D28BQ35842270-C63FB12B-EA3C-4B5D-A595-DBD2445BFD4DQ36282702-5FA9F80D-3337-4F49-A630-E5B8C456330CQ36406259-A1A27C4F-3B62-480D-85A0-96225E50D2E4Q36410175-F9091F2A-97D9-4968-BCCF-0017150E00AAQ37383949-9D074CB4-34F4-4FBD-93EA-87A021846E74Q37463268-4C3513C6-2A27-44CF-9042-D6AD5CB1853BQ37538717-726ECDC3-B99F-4D4C-A962-C49A401E8DC3Q37801927-D52FFEA1-65B5-416E-99A5-F3273E1F2701Q37864141-458699AC-BD5E-4175-87D4-F84C5AEE5402Q37950517-C374DF6D-C404-4629-B6E5-835BE22A340FQ38083294-17C32E7F-A9EE-46C1-BF5C-E1DC86D4D88DQ38272654-5C964D34-5A12-4766-9213-D5EE8BA7392DQ39383647-0B63CEB4-752F-4B40-B832-7445598B45F1Q39519582-93686CF2-5B20-4CA7-9A81-FCF9DEE5E5E3Q41686484-031CE83B-08D9-4CB8-B3D4-1CE5CCBFB18DQ42207342-A1547E2A-CA14-449E-B3B2-76AB9591E73DQ43104680-B2F8509F-444A-40C1-A6A4-E60C7427EC58Q43645570-7A836272-DF99-4454-BBEA-23F257778871Q46102935-3F5FDBDD-9003-4171-9907-06FA4CB6F3D7Q46667661-8F6E98A8-A398-40F9-9CE9-7E41B6AE59E3Q46923095-04EC0427-F546-4754-A91B-137DCD526B09Q47375821-B64223CD-52F1-4211-870B-E3CF1C49EC0AQ47718267-91AC77CC-1BC8-48CF-A3F2-12146BFF2B14Q48485316-E7320192-2BF4-48C9-86BB-CE34FCAC63B9Q50028053-0DB450F6-FB03-43EC-83B8-88B33B7F164AQ54915406-BA389363-A15E-4BAE-9748-A931F5CE1EF4Q55344050-C2E68C58-15A5-49CC-8B7C-DAAFC13870BEQ57831810-085FEEF7-DA0B-45FA-8209-CC193EC5CC4A
P2860
Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Safety and tolerance of efavir ...... n 1,033 HIV-infected patients.
@en
Safety and tolerance of efavir ...... n 1,033 HIV-infected patients.
@nl
type
label
Safety and tolerance of efavir ...... n 1,033 HIV-infected patients.
@en
Safety and tolerance of efavir ...... n 1,033 HIV-infected patients.
@nl
prefLabel
Safety and tolerance of efavir ...... n 1,033 HIV-infected patients.
@en
Safety and tolerance of efavir ...... n 1,033 HIV-infected patients.
@nl
P2860
P1433
P1476
Safety and tolerance of efavir ...... n 1,033 HIV-infected patients.
@en
P2860
P304
P356
10.1310/3Q91-YT2D-BUT4-8HN6
P577
2002-07-01T00:00:00Z